RecruitingPhase 1NCT07255846

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

Studying Hereditary hemorrhagic telangiectasia

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Terremoto Biosciences Inc.
Intervention: TER-1754(drug)
Enrollment: 90 enrolled
Eligibility: 18 years · All sexes
Timeline: 2025 – 2028

Study locations (1)

Innovative Hematology, Inc., Indianapolis, Indiana, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07255846 on ClinicalTrials.gov

Other trials for Hereditary hemorrhagic telangiectasia

Additional recruiting or active studies for the same condition.

ENROLLING BY INVITATIONNCT07445347
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
Poitiers University Hospital
RECRUITINGPHASE1, PHASE2NCT06659640
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Alnylam Pharmaceuticals
ACTIVE NOT RECRUITINGNCT07018401
Pomalidomide for the Treatment of Bleeding in Hereditary Hemorrhagic Telangiectasia Longitudinal Assessment Study
Massachusetts General Hospital
ENROLLING BY INVITATIONNCT06261333
Quality of Life in Patients With Hemorrhagic Telangiectasia
University Hospital, Essen
ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT03850964
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
Cure HHT
RECRUITINGNANCT05641142
Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
University Hospital, Clermont-Ferrand
ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05406362
Assess Safety and Efficacy of VAD044 in HHT Patients
Vaderis Therapeutics AG
RECRUITINGPHASE2NCT04976036
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Dr. Romain Lazor

See all trials for Hereditary hemorrhagic telangiectasia →

← Back to all trials